Sanofi Signs an Agreement with Kymera to Advance Novel Protein Degrader Therapies Worth Up to $2.1B
Shots:
- Kymera to receive $150M up front- $2B as development- regulatory and commercial milestones along with royalties on sales of therapies. Additionally- the company has an option to develop and commercialize the two programs in the US while retaining global rights to its IRAK4 program in oncology indications.
- Sanofi will get a global right to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases and a second undisclosed preclinical program
- Kymera will advance the IRAK4 program through the P-I study- afterward- Sanofi will be further responsible for its development and will lead all clinical development activities for the second program. IRAK4 is a key protein involved in inflammation mediated by the activation of TLRs and IL-1Rs
Click here to read full press release/ article | Ref: PRNewswire | Image: WRVO
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
